FDA hands As­traZeneca-Am­gen broad ap­proval for asth­ma an­ti­body, clear­ing block­buster path

Af­ter last year’s Phase III re­sults, there was lit­tle ques­tion that the FDA would ap­prove Am­gen and As­traZeneca’s long-in­cu­bat­ing an­ti­body for asth­ma, bar­ring any man­u­fac­tur­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER